Authorities probing ‘counterfeit’ rabies vaccine, says drug regulator
The manufacturer of the vaccine has denied producing the ‘misbranded’ vials bearing batch number KE25012 which failed a potency test by the Central Drugs Laboratory
The Central Drugs Laboratory (CDL) in India has flagged a batch of the rabies vaccine Abhayrab, labeled KE25012, as not meeting standard quality and misbranded after failing a potency test. The batch was seized on April 22 from an unlicensed residential premises during an enforcement action by Delhi Police and officials from Delhi’s Drugs Control Department.
Four individuals have been arrested in connection with the incident, and the Central Drugs Standard Control Organisation (CDSCO) has initiated an investigation to determine the manufacturer of the suspect vials and whether any patients received them. The CDSCO has requested all State Drugs Controllers to maintain strict vigilance over the movement, distribution, and availability of batch KE25012 of Abhayrab.
The manufacturer, Indian Immunologicals Ltd. (IIL), has confirmed that the batch was not produced by the company and that the seized vials do not match the genuine product. The investigation aims to identify the source and distribution of the counterfeit vaccine and ensure the quality and safety of medicines available to the public.
Brief written by urgent.news from The Hindu's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
